Phase 2/3 study in 3rd or 4th line treatment in metastatic colorectal cancer2019-04-08T11:42:06+00:00

Project Description

Phase 2/3 study in 3rd or 4th line treatment in metastatic colorectal cancer

Brief

Colorectal cancer is also known as bowel cancer and colon cancer. Colorectal cancer is a disease originating from the epithelial cells lining the colon or rectum of the gastrointestinal tract. Most colorectal cancers are due to old age and lifestyle factors with only a small number of cases due to underlying genetic disorders.

R.G.L has been mandated by a biotechnology company to lead an international and competitive phase 2/3 study in Israel to prove the efficacy and safety of their molecule in metastatic colorectal cancer.

Goals

  • To find 3 medical centers with a high rate of patients recruitment 
  • To sign with all 3 centers a Clinical Trial Agreement and negotiate a budget per patient according to Sponsor’s guidelines and recommendations 
  • To obtain Local Ethical Committee approvals in the conduct of the Trial 
  • To obtain Ministry of Health’s approval in the conduct of the Trial for Israel, 
  • To recruit 100% of the recruitment patient potential (25 patients) in 12 months

Want To Work With Us?

WE WILL BE HAPPY TO WORK WITH YOU.

Contact Us